Abstract:OBJECTIVE: To determine the effects of antiplatelet therapy among patients at high risk of occlusive vascular events.DESIGN: Collaborative meta-analyses (systematic overviews).INCLUSION CRITERIA: Randomised trials of an antiplatelet regimen versus control or of one antiplatelet regimen versus another in high risk patients (with acute or previous vascular disease or some other predisposing condition) from which results were available before September 1997. Trials had to use a method of randomisation that precluded prior knowledge of the next treatment to be allocated and comparisons had to be unconfounded-that is, have study groups that differed only in terms of antiplatelet regimen.STUDIES REVIEWED: 287 studies involving 135 000 patients in comparisons of antiplatelet therapy versus control and 77 000 in comparisons of different antiplatelet regimens.MAIN OUTCOME MEASURE: "Serious vascular event": non-fatal myocardial infarction, non-fatal stroke, or vascular death.RESULTS: Overall, among these high risk patients, allocation to antiplatelet therapy reduced the combined outcome of any serious vascular event by about one quarter; non-fatal myocardial infarction was reduced by one third, non-fatal stroke by one quarter, and vascular mortality by one sixth (with no apparent adverse effect on other deaths). Absolute reductions in the risk of having a serious vascular event were 36 (SE 5) per 1000 treated for two years among patients with previous myocardial infarction; 38 (5) per 1000 patients treated for one month among patients with acute myocardial infarction; 36 (6) per 1000 treated for two years among those with previous stroke or transient ischaemic attack; 9 (3) per 1000 treated for three weeks among those with acute stroke; and 22 (3) per 1000 treated for two years among other high risk patients (with separately significant results for those with stable angina (P=0.0005), peripheral arterial disease (P=0.004), and atrial fibrillation (P=0.01)). In each of these high risk categories, the absolute benefits substantially outweighed the absolute risks of major extracranial bleeding. Aspirin was the most widely studied antiplatelet drug, with doses of 75-150 mg daily at least as effective as higher daily doses. The effects of doses lower than 75 mg daily were less certain. Clopidogrel reduced serious vascular events by 10% (4%) compared with aspirin, which was similar to the 12% (7%) reduction observed with its analogue ticlopidine. Addition of dipyridamole to aspirin produced no significant further reduction in vascular events compared with aspirin alone. Among patients at high risk of immediate coronary occlusion, short term addition of an intravenous glycoprotein IIb/IIIa antagonist to aspirin prevented a further 20 (4) vascular events per 1000 (P<0.0001) but caused 23 major (but rarely fatal) extracranial bleeds per 1000.CONCLUSIONS: Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation. Low dose aspirin (75-150 mg daily) is an effective antiplatelet regimen for long term use, but in acute settings an initial loading dose of at least 150 mg aspirin may be required. Adding a second antiplatelet drug to aspirin may produce additional benefits in some clinical circumstances, but more research into this strategy is needed.

Effects of Different Antithrombotic Interventions on Platelet Activation in Patients with Atrial Fibrillation

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Clinical study of cerebral infarction prevention with warfarin in nonvalvular atrial fibrillation

Effects of Atorvastatin and Aspirin on the Levels of Plasma Lysophospholipids and the Incidence of Stroke in Patients with Atrial Fibrillation

Effect of Pretreatment with Aspirin and Ticlopidine on the Change of Platelet Aggregability after Radiofrequency Catheter Ablation

Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation

Safety of Early Antiplatelet Therapy for Non-Cardioembolic Mild Stroke Patients with Thrombocytopenia.

Influence of Aspirin on Plasma Levels of Lysophosphatidic Acid in Patients with Ischemic Cerebrovascular Diseases

Evaluating the effect of different doses of aspirin on the platelet inhibition rate by thromboelastography

Comparison of dual-antiplatelet treatment with warfarin for the prevention of thromboembolism in low risk patients with nonvalvular atrial fibrillation

The Clinical Observation Of Anticoagulants And Antithrombotic Therapy In Elderly Patients With Atrial Fibrillation

Effects of atorvastatin on the levels of plasma lysophospholipids and the incidence of stroke in patients with atrial fibrillation

The Control Study of Treatment Between Dual-Antiplatelet Aggregation and Warfarin in the Prevention of Thromboembolism in High Risk Patients of Nonvalvular Atrial Fibrillation GENG

Comparison of the efficacy and safety of warfarin anticoagulation and left atrial appendage transcatheter occlusion in the treatment of non-valvular atrial fibrillation and investigation of ET-1, hs-CRP and PDGFs

The effect of different initial warfarin dose on the target international normalized ratio in patients with nonvalvular atrial fibrillation or atrial flutter

[The Randomized Study of Efficiency and Safety of Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Warfarin Compared with Aspirin].

Effect of Amlodipine on Platelet Inhibition by Clopidogrel in Patients with Ischaemic Heart Disease: a Randomised, Controlled Trial

An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions

Anti-aggregation Effect and Short-term Safety Evaluation of Low-dose Aspirin Therapy in the Elderly Chinese Population: a Multicenter Randomized Controlled Clinical Trial

Comparison of Different Laboratory Tests to Identify "Aspirin Resistance" and Risk of Vascular Events among Ischaemic Stroke Patients: A Double-Blind Study

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients